FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition

Novo Nordisk files lawsuit to protect patient access challenging the Inflation Reduction Act’s drug pricing scheme as unconstitutional and the Centers for Medicare and Medicaid Services’ actions as unlawful

Novo Nordisk and Evotec collaborate to launch LAB eN², a translational drug discovery accelerator, to address innovation gap in cardiometabolic diseases